Idelalisib (CAL-101)
别名: GS-1101 中文名称：艾代拉里斯，艾代拉利司
Idelalisib (CAL-101)是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 还可诱导自噬。
Idelalisib (CAL-101) Chemical Structure
CAS: 870281-82-6
相关PI3K产品
客户使用Selleck的Idelalisib (CAL-101)发表文献260篇：
产品质控
批次：
纯度：
99.93%
99.93
PI3K抑制剂选择性比较
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息 |
|---|---|---|---|---|---|
| MEC1 | NXLkflNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= | M4TJb2lEPTB;MkCuOEDPxE1? | NGHGeYI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm5PVM2Oid-MkW5PVk{PTJ:L3G+ | ||
| CLL PBMCs | MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? | NIrTWJFKSzVyPUKuPUBvVQ>? | NUS0NVZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5NVczPjdpPkK1PVE4OjZ5PD;hQi=> | ||
| U266 | MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? | NXzMcopjPDBizszN | NWG3OogzPDhiaB?= | MYm3PU42LSCrbnjpZol1cW:wIILheIU> | MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN|OUOzNkc,OjV|M{mzN|I9N2F- |
| K562 | NFHl[VNHfW6ldHnvckBCe3OjeR?= | M1PhcFEh|ryP | MmnnN{Bp | M3TXfGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= | NHy3ZoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+ |
| K562 | M2DWN2Z2dmO2aX;uJGF{e2G7 | NWjjWmpuOSEQvF2= | MkG4N{Bp | NE\6[YtKdmirYnn0bY9vKG:oIGC3NHM3UyCyaH;zdIhwenmuYYTpc44> | NEf5NnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+ |
| K562 | M2jLVmZ2dmO2aX;uJGF{e2G7 | MX6xJO69VQ>? | MoG2N{Bp | NUHyOXhbUW6qaXLpeIlwdiCxZjDHV2s{KHCqb4PwbI9zgWyjdHnvci=> | MlX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O|UoRjJ3MEG0O|c2RC:jPh?= |
| K562 | MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? | MXqxJO69VQ>? | NF3uXnA4OiCq | NFPGcGRKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44> | NVfIUmNsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=> |
| Primary AML cell | M3rkW2Z2dmO2aX;uJGF{e2G7 | NGjkOmwyKM7:TR?= | NIPx[3Q{KGh? | NIjSdnNKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= | NHfKOZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+ |
| Primary AML cell | MWHGeY5kfGmxbjDBd5NigQ>? | Ml3QNUDPxE1? | M3v3O|MhcA>? | MkDDTY5pcWKrdHnvckBw\iCSN{DTOmsheGixc4Doc5J6dGG2aX;u | NELsZZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCxOFc4PSd-MkWwNVQ4PzV:L3G+ |
| Primary AML cell | NX\nRVVsTnWwY4Tpc44hSXO|YYm= | MX6xJO69VQ>? | NGjIbIs{KGh? | NEHJe5VKdmirYnn0bY9vKG:oIFfTT|MheGixc4Doc5J6dGG2aX;u | NU\mXXEzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNVQ4PzVpPkK1NFE1Pzd3PD;hQi=> |
| Primary AML cell | M3fCRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 | NETXO4EyKM7:TR?= | MWSzJIg> | NELZPFVUfXCycnXzd4lwdiCxZjDyVm5CKHO7boTo[ZNqew>? | MlLMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMUS3O|UoRjJ3MEG0O|c2RC:jPh?= |
| Microglia | NHWyPFlHfW6ldHnvckBCe3OjeR?= | MWq1JO69VQ>? | Mo\yNVAhcA>? | NHPXNG9F\WO{ZXHz[UBw\iCWTl\hJJNm[3KndHnvckBnem:vIFzQV{1{fGmvdXzheIVlKCCyMUGw{tRFQTFyQT;EPVExSSCvaXPyc4dtcWF? | NGDNWW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[yOVY5PCd-MkS2NlU3QDR:L3G+ |
| Primary CLL cell | NEn0[GdHfW6ldHnvckBCe3OjeR?= | NFexVVIyKM7:TR?= | NET5VYwyPSCvaX6= | NVHGT3dFSmyxY3vzJGJEWi2rbnT1Z4VlKEyFUEGgd4VzcW6nLUWgZYN1cX[jdHnvci=> | NITte5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwPVI{Oyd-MkSwNFkzOzN:L3G+ |
| JEKO-1 | MmLLSpVv[3Srb36gRZN{[Xl? | NWqyVW11OSEQvF2= | NH;tfHQ4OiCq | M4XSZmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF? | MnLuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN|NEG1OFEoRjJ|M{SxOVQyRC:jPh?= |
| Granta-519 | NXe5[IFbTnWwY4Tpc44hSXO|YYm= | Mk\lNUDPxE1? | NVzsTY5iOiCq | NWHCVY5SUW6qaXLpeIlwdiCxZjDBb5QpfDNyODmgdIhwe3Cqb4L5cIF1cW:w | NFnOfnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{O0NVU1OSd-MkOzOFE2PDF:L3G+ |
| Granta-519 | NFPkdmJHfW6ldHnvckBCe3OjeR?= | NV\HZmlVOSEQvF2= | MYiyJIg> | NFPIcW1KdmirYnn0bY9vKG:oIFHreEh{PDd|KTDwbI9{eGixconsZZRqd25? | M37zdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{SxOVQyLz5{M{O0NVU1OTxxYU6= |
| JEKO-1 | NYnWfYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= | NFzXbZgyOCEQvF2= | NIfUZnE4OiCq | NGHLXWFKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44he2yrZ3j0cJk> | MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN2MUW0NUc,OjN|NEG1OFE9N2F- |
| JEKO-1 | NXjkcI1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= | NYPQdVh[PSEQvF2= | MXG3NkBp | M4O3T4Rw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> | MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ5NkKyNEc,OjN4N{[yNlA9N2F- |
| MAVER-1 | MlnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? | NHnE[mE2KM7:TR?= | M3jiVlczKGh? | M2\LPIRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> | NHT4bpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O|YzOjB:L3G+ |
| MINO | M{[zZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 | MXe1JO69VQ>? | NYTnSYZbPzJiaB?= | Mors[I9meyCwb4SgbY5lfWOnIHPlcIwh[3mlbHWgZZJz\XO2IH;yJIFxd3C2b4Ppdy=> | NELTbZY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[3OlIzOCd-MkO2O|YzOjB:L3G+ |
| SP53 | NULrWJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= | M1r4bVAvOSEQvF2= | NGLadXY4OiCq | M3;BWIRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> | M{TPZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|Nke2NlIxLz5{M{[3OlIzODxxYU6= |
| HH | NHjlS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= | MXGxNEDPxE1? | NEDHUmM4OiCq | NXHEZlBJUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDzcIlocHSueR?= | M2L1O|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6= |
| Myla | M{f5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 | NFXV[lUyOCEQvF2= | MnjTO|IhcA>? | NWjqdY5y\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> | NF3ZcFU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+ |
| SR786 | NEewRVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= | MljTNVAh|ryP | Mof1O|IhcA>? | NVr0e3dU\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> | NG\NT3c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiwNVk2QSd-MkK4NFE6PTl:L3G+ |
| HuT78 | M2PtRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 | NVPlN5VvOTBizszN | MmrEO|IhcA>? | Mlf1[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= | MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjhyMUm1PUc,OjJ6MEG5OVk9N2F- |
| MJ | MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? | M2[4SVExKM7:TR?= | NVH0WHh4PzJiaB?= | NG\xb21ld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz | M4P2cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OECxPVU6Lz5{MkiwNVk2QTxxYU6= |
| DERL7 | NH\kUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= | NIL1UmQyOCEQvF2= | NHrwVXI4OiCq | NUnlWplG\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> | MlzTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6MEG5OVkoRjJ{OECxPVU6RC:jPh?= |
| L1236 | NGraZmdHfW6ldHnvckBCe3OjeR?= | MmDFNVAh|ryP | MlGwNkBp | M1rhd2lvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= | NFfCOGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkKxNFg4Pyd-MkKyNVA5Pzd:L3G+ |
| L428 | MWfGeY5kfGmxbjDBd5NigQ>? | Mn7qNVAh|ryP | MWCyJIg> | NHnHSYlKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= | MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F- |
| L591 | Mom4SpVv[3Srb36gRZN{[Xl? | NV\ob5llOTBizszN | NXrNS|dGOiCq | M4LhTmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= | MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F- |
| KMH-2 | NXPZZnhYTnWwY4Tpc44hSXO|YYm= | Mlu2NVAh|ryP | MmXHNkBp | M4qxZWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= | NU\F[FZ6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNVA5PzdpPkKyNlExQDd5PD;hQi=> |
| L1236 | MV7GeY5kfGmxbjDBd5NigQ>? | M1PXWFUh|ryP | MXiyOEBp | MYLCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1 | Mn3OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O|coRjJ{MkGwPFc4RC:jPh?= |
| L591 | MmLTSpVv[3Srb36gRZN{[Xl? | NFLqO442KM7:TR?= | MWCyOEBp | NWLZbmM{SmyxY3vzJJNm[3KndHnvckBw\iC2aHWgR2NNPQ>? | MoP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{MUC4O|coRjJ{MkGwPFc4RC:jPh?= |
| L1236 | NFHCPZVCeG:ydH;zbZMhSXO|YYm= | NXvuc2FNPSEQvF2= | NILPVmUzPCCq | NYLicnJmUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= | MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F- |
| L591 | NWjXZ5NFSXCxcITvd4l{KEG|c3H5 | NYHs[5lrPSEQvF2= | NYPqXY9vOjRiaB?= | M4XpXmlv\HWldHnvckBw\iCjcH;weI9{cXN? | MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJzMEi3O{c,OjJ{MUC4O|c9N2F- |
| U-87MG | NFvuTYRHfW6ldHnvckBCe3OjeR?= | NGfQZnAyODBibl2= | NFzYWWYzPCCq | MlrSTY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44> | NGnxXJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkC3PVYxQSd-MkKwO|k3ODl:L3G+ |
| SW1783 | MkPESpVv[3Srb36gRZN{[Xl? | MV[xNFAhdk1? | NETNe44zPCCq | NILHVYNKdmirYnn0bY9vKG:oIDDj[YxtKG2rZ4LheIlwdg>? | NX:2ZXNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=> |
| U-87MG | MXnGeY5kfGmxbjDBd5NigQ>? | M{LLVlUh|ryP | M{fXUlI1KGh? | MXrJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=> | NWrpdFBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=> |
| SW1783 | MkH3SpVv[3Srb36gRZN{[Xl? | NUDmVHRzPSEQvF2= | MUCyOEBp | MofYTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> | MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5OU[wPUc,OjJyN{m2NFk9N2F- |
| U-373MG | MW\GeY5kfGmxbjDBd5NigQ>? | MmriOUDPxE1? | NYrpdXdZOjRiaB?= | NX;0e5c3UW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? | NWDTbZc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwO|k3ODlpPkKyNFc6PjB7PD;hQi=> |
| SK-MG3 | M3u4WmZ2dmO2aX;uJGF{e2G7 | MXO1JO69VQ>? | NGPPTYIzPCCq | NH7LeJVKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? | M1\EOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEe5OlA6Lz5{MkC3PVYxQTxxYU6= |
| SU-DHL-5 | M13JZmZ2dmO2aX;uJGF{e2G7 | MW[xJO69VQ>? | MX6yOEBp | NInCXXJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| | MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODl3OU[wOkc,OjB7NUm2NFY9N2F- |
| WSU-NHL | NWX6[pFHTnWwY4Tpc44hSXO|YYm= | MljZNUDPxE1? | MWWyOEBp | NYjFSXJbUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= | NYXLV5ZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5OVk3ODZpPkKwPVU6PjB4PD;hQi=> |
| CCRF-SB | NEX2Vm5HfW6ldHnvckBCe3OjeR?= | NV3Ie213OSEQvF2= | MXSyOEBp | NVnq[oY3UW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= | NILmNW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEm1PVYxPid-MkC5OVk3ODZ:L3G+ |
| INA-6 | MlPKSpVv[3Srb36gRZN{[Xl? | M1nH[VUh|ryP | M3XSSlYhcA>? | NF7sd5VKdmirYnn0bY9vKG:oIGDJN2swSWu2IHHu[EBGWkticHH0bJdigQ>? | NF7w[ng9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWwOVE2QCd-MkC1NFUyPTh:L3G+ |
| LB | NEHEb4tHfW6ldHnvckBCe3OjeR?= | MlztOUDPxE1? | NHqzOoI3KGh? | M1P1RWlvcGmkaYTpc44hd2ZiUFm0T{9Cc3RiYX7kJGVTUyCyYYToe4F6 | NETYb3M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEWwOVE2QCd-MkC1NFUyPTh:L3G+ |
| B-cells | MkmxSpVv[3Srb36gZZN{[Xl? | NUXk[414UW6qaXLpeIlwdiCxZjDQTVNM\GWudHGgbY4hSi2lZXzsd{BjgSCycn;sbYZmemG2aX;uJIF{e2G7LDDJR|UxKD1iMD6wNFYyKM7:TT6= | MmjWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7MkS2PFgoRjJ{OUK0Olg5RC:jPh?= | ||
| MOLM14 | M3TOWGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 | MV6zJIRigXN? | NUj3e4k1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEmFNUCgQUA{NjZizszNMi=> | NEKyVno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+ | |
| MV4-11 | MUDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? | M1;DS|Mh\GG7cx?= | NGGwSXVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3WOE0yOSClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFYvOyEQvF2u | MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd5N{SxNlcoRjJ5N{e0NVI4RC:jPh?= | |
| Jurkat | M4n2NmFvfGmycn;sbYZmemG2aY\lJIF{e2G7 | MX:zJIRigXN? | MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEq3cnvheEBk\WyuczDh[pRmeiB|IHThfZMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEeuPUDPxE1w | NUXC[4poRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke3O|QyOjdpPkK3O|c1OTJ5PD;hQi=> | |
| Loucy | NWLJN21TSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= | M{nEflMh\GG7cx?= | MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEyxdXP5JINmdGy|IHHmeIVzKDNiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR|UxKD1iOD60JO69VS5? | M2jRNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5N{e0NVI4Lz5{N{e3OFEzPzxxYU6= | |
| MOLT4 | NVnafGc2SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= | MXuzJIRigXN? | NWHFVIhnSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xVPCClZXzsd{Bi\nSncjCzJIRigXNiYomgR4VtdFSrdHXyMWdtdyCjc4PhfUwhUUN3MDC9JFExNjZizszNMi=> | NF[3bXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{e3OFEzPyd-Mke3O|QyOjd:L3G+ | |
| insect cells | NFG3VopHfW6ldHnvckBie3OjeR?= | M3WxO2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigTIl{NXSjZ3fl[EBRUTONZ3HtcYEh\XiycnXzd4VlKGmwIHnud4VkfCClZXzsd{whUUN3MDC9JFAvODh7IN88UU4> | MmX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?= | ||
| SUDHL6 | NGjkW|NCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= | NYfWWXpwPzJiaILz | M2TyfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU2XETGw3KGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OCB;IECuNVE4PiEQvF2u | MoPyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd6NE[0OVEoRjJ5OES2OFUyRC:jPh?= | |
| insect cells | Mkn1SpVv[3Srb36gZZN{[Xl? | MVvJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKG[3bHygcIVv\3SqIFjpd{11[WepZXSgVGk{U2KndHGg[ZhxemW|c3XkJIlvKGmwc3XjeEBk\WyuczygTWM2OCB;IECuOVY2KM7:TT6= | NGryUVU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{i0OlQ2OSd-Mke4OFY1PTF:L3G+ | ||
| SU-DHL4 | NYPRPVhOSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= | NYfPSYk{PzJiaILz | NEDmWmdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPVMWRJVDRiY3XscJMhdWWjc4Xy[YQh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MEBKSzVyIE2gNU43KM7:TT6= | M{fuR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5OES2OFUyLz5{N{i0OlQ2OTxxYU6= | |
| Pfeiffer | M4judWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 | NGfpWnI4OiCqcoO= | NFT3PIFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDm[Yln\mW{IHPlcIx{KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3MDC9JFYvQCEQvF2u | NV60eXhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=> | |
| KARPAS422 | NHfofHNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= | M1vEdlczKGi{cx?= | NUe5c4FISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDLRXJRSVN2MkKgZ4VtdHNibXXhd5Vz\WRiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwJF0hQC5zIN88UU4> | NV7J[5FFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4OFY1PTFpPkK3PFQ3PDVzPD;hQi=> | |
| Sf21 | MnTlSpVv[3Srb36gZZN{[Xl? | MmXjN|AhdWmwcx?= | MWjJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiSHnzOk11[WepZXSgdoVkd22kaX7hcpQh\nWubD3s[Y5ofGhiaIXtZY4hWEl|SzDwNVEx[mW2YT;1cpRi\2enZDDy[YNwdWKrbnHueEBnfWyuIHzlcod1cCCqdX3hckBxQDWjbIDoZUBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4YzOSCrboPlZ5Qh[2WubIOgeZNqdmdiUFnQNk9CXFBiYYOgd5Vje3S{YYTlJIFnfGW{IEOwJI1qdnNiYomgWHIuTlKHVDDhd5NigSxiSVO1NEA:KDNwNzFOwG0v | MnjZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjhzME[5PVEoRjJ6MUC2PVkyRC:jPh?= | |
| Sf21 | M{TxOmZ2dmO2aX;uJIF{e2G7 | MXezNEBucW6| | M1nTXmlvcGmkaYTpc44hd2ZiTj30[ZJucW6jbDDIbZM3NXSjZ3fl[EBz\WOxbXLpcoFvfCCodXzsMYxmdme2aDDoeY1idiCSSUPLJJAyOTCkZYThM5VvfGGpZ3XkJJJm[2:vYnnuZY51KG[3bHygcIVv\3SqIHj1cYFvKHB6NXHsdIhiKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jJzIHnud4VkfCClZXzsd{B2e2mwZzDQTXAzN0GWUDDhd{B{fWK|dILheIUh[W[2ZYKgN|AhdWmwczDifUBVWi2IUlXUJIF{e2G7LDDJR|UxKD1iMz63JO69VS5? | NHHmdI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEGwOlk6OSd-MkixNFY6QTF:L3G+ | |
| RPMI8266 | MoPORY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? | M3nqTVczKGi{cx?= | MkHZRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUUF3JPFI3PiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xODV2OTFOwG0v | NE\PVVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEOyOVYxOSd-MkizNlU3ODF:L3G+ | |
| Raji | NFS1ZW9CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= | MoDZO|IhcHK| | MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFKjanmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEC5PVUh|ryPLh?= | MkT3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|MkW2NFEoRjJ6M{K1OlAyRC:jPh?= | |
| KARPAS422 | M4LpNGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 | NWjuVHB5T3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hU0GUUFHTOFIzKGOnbHzzJIJ6KEOFS{igZZN{[XluIFfJOVAhRSByLk[4JO69VS5? | NHn4[ZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEizOVgxPSd-Mki4N|U5ODV:L3G+ | ||
| Pfeiffer | NIPNfWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= | NFfEeoxIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBR\mWrZn\ldkBk\WyuczDifUBES0t6IHHzd4F6NCCJSUWwJF0hOC55NDFOwG0v | MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDh|NUiwOUc,Ojh6M{W4NFU9N2F- | ||
| Saos-2 | M3\aVJFJXFNiYYPzZZk> | NHnNepJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz | M1zBV|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6= | ||
| SK-N-SH | M1y5eJFJXFNiYYPzZZk> | MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= | NXv6WHBNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=> | ||
| MG 63 (6-TG R) | MmDGdWhVWyCjc4PhfS=> | NHPkNW1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTVegOlMhMDZvVFegVkkh[2WubIO= | MlLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?= | ||
| NB1643 | M4TjNpFJXFNiYYPzZZk> | M{fONJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO= | M{fIXVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6= | ||
| OHS-50 | M4e3eZFJXFNiYYPzZZk> | MUHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| | MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F- | ||
| Rh41 | NXS1WG9oeUiWUzDhd5NigQ>? | MoLpdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? | NX\4[W9LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=> | ||
| SK-N-MC | MlfTdWhVWyCjc4PhfS=> | MkO0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO= | NWixOYFQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=> | ||
| NB-EBc1 | MWrxTHRUKGG|c3H5 | MkTEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6ELVXCZ|Eh[2WubIO= | MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F- | ||
| LAN-5 | MUjxTHRUKGG|c3H5 | M2TtbZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?= | MmnEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?= | ||
| SUDHL6 | MoHrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? | NWW5WJhiPzJiaILz | NWnQOFRDSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTWWRJVDZiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUAxNjZ3IN88UU4> | MnX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5N|YoRjJ7NUO0PVM3RC:jPh?= | |
| RPMI8226 | M2TvcWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 | MYG3NkBpenN? | Mn7QRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCUUF3JPFIzPiClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gOU41QSEQvF2u | Mn3VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5N|YoRjJ7NUO0PVM3RC:jPh?= | |
| Raji | NUnaXGJzSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= | NWjUWWl5PzJiaILz | NFPR[lNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGLhbokh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEmuPVUh|ryPLh?= | MmHDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3M{S5N|YoRjJ7NUO0PVM3RC:jPh?= | |
| SU-DHL6 | NXG3NItpT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= | NFPBclVIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBUXS2GSFy2JINmdGy|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEeLNUCgQUAxNjB2MjFOwG0v | MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTZyMUm5NUc,Ojl4MEG5PVE9N2F- | ||
| MOLM13 | NVvz[FFkT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= | NYjR[FNQPzJiaILz | NF7xU4RIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBOV0yPMUOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOnbHzUbZRmei2JbH:gcJVucW6nc3PlcpQh[XO|YYmsJGdKPTBiPTCxMlch|ryPLh?= | NIjy[Y09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC1N|czOSd-M{CwOVM4OjF:L3G+ | |
| MOLM14 | MXzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? | NECzRpE4OiCqcoO= | MYnHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDNU2xOOTRiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JGNmdGyWaYTldk1IdG9ibIXtbY5me2OnboSgZZN{[XluIFfJOVAhRSB4LkSg{txONg>? | NVr5S5BlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=> | |
| MOLM14 | MUjBcpRqfHWvb4KgZZN{[Xl? | Mn3ONVAxKG2pL3vn | MVKxOEBl[Xm| | M3ruVGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyC2dX3vdkBoem:5dHigbY5pcWKrdHnvckBifCBzMECgcYcwc2duIIDvJIFldWmwaYP0[ZJm\CCmYXnsfUB3cWFiZ3H2ZYdmKGSxc3XkJIZweiBzNDDkZZl{KGGwZDDt[YF{fXKnZDDkZYltgSCmdYLpcoch[2:vcH;1coQh\G:|aX7nJJJmdGG2aY\lJJRwKGOxboTyc4w> | NV\vXFZXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOVM4OjFpPkOwNFU{PzJzPD;hQi=> |
| MOLM14 | Ml;yRY51cXS3bX;yJIF{e2G7 | M{O4bFExOCCvZz;r[y=> | MWqxOEBl[Xm| | MYXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVQh[2WubIOgfIVvd2e{YX\0[YQhcW5iboWvcpUhdW:3c3WgZZN{\XO|ZXSgZZMhcW6mdXP0bY9vKG:oIHHwc5B1d3OrczDheEAyODBibXevb4ctKHCxIHHkcYlvcXO2ZYLl[EBl[WmueTD2bYEh\2G4YXflJIRwe2WmIH\vdkAyPCCmYYnzJIFv\CCvZXHzeZJm\CCmYXnsfUBlfXKrbnegZ49ueG:3bnSg[I9{cW6pIHL5JHRWVkWOIHLhd4VlKGG|c3H5 | NHrKNVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEC1N|czOSd-M{CwOVM4OjF:L3G+ |
| MOLM14 | NHzKUIZCdnSrdIXtc5Ih[XO|YYm= | NHi3Tm8yODBibXevb4c> | NIfQfYUyPCCmYYnz | M2DlemFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3PUG0yPCClZXzsd{B5\W6xZ4Lh[pRm\CCrbjDueU9vfSCvb4Xz[UBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJJR2dW:{IIDyc4xq\mW{YYTpc44hOTByIH3nM4toNCCybzDh[I1qdmm|dHXy[YQh\GGrbImgeoliKGejdnHn[UBld3OnZDDmc5IhOTRiZHH5d{BidmRibXXhd5Vz\WRiZHHpcJkh\HW{aX7nJINwdXCxdX7kJIRwe2mwZzDifUBMcS14NzDsZYJmdGyrbnegZoF{\WRiaX3teY5wcA>? | MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB3M{eyNUc,OzByNUO3NlE9N2F- |
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | Idelalisib (CAL-101)是选择性p110δ抑制剂，在无细胞试验中IC50为 2.5 nM；对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍，对p110δ的选择性是对 C2β，hVPS34，DNA-PK 和 mTOR的400到4000倍。Idelalisib 还可诱导自噬。 | ||||
|---|---|---|---|---|---|
| 特性 | Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。 | ||||
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达，EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比，CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞，降低pAktS473, pAktT308, 和下游靶点S6， EC50为0.1到1.0 μM。 [1] CAL-101 作用于CLL细胞，诱导选择性细胞毒性，不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比，CAL-101作用于CLL 细胞优先产生细胞毒性，和LY294002相比，作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞 缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累，在S期下降，说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。[3] |
|||
|---|---|---|---|---|
| 激酶实验 | PI3K实验 | |||
| 用全CLL和正常B细胞溶解物进行PI3K实验。 进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer（包含 ATP)的混合物中，在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合，反应终止，在室温下温育1小时。混合物转移到PI3K ELISA板上，再温育1小时。 冲洗反应板，然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液 ，反应5分钟，加入H2SO4 终止反应。在450纳米处读数。 | ||||
| 细胞实验 | 细胞系 | CLL B 细胞或健康志愿者的T细胞或NK细胞 | ||
| 浓度 | 0.01-100 μM | |||
| 孵育时间 | 48小时 | |||
| 方法 | 进行MTT实验测定细胞毒性。1×105个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时，然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力，分析数据。每个样本至少计数104个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。 基质共培养 在75cm2培养瓶 (80%-100% 融合率) 培养24 小时，然后加入CLL细胞。 |
|||
| 实验图片 | 检测方法 | 检测指标 | 实验图片 | PMID |
| Western blot | PUMA / p53 Bim / Bcl-xl / Bid / Mcl-1 p-p65 p-AKT / AKT Cleaved caspase 3 / Cleaved caspase 9 Mcl-1 / Bcl-2 / Bid / Bcl-xl / Noxa / Bak / Bax p-FoxO3a / FoxO3a Akt(T308) / PDK1(S241) / GSK-3β(S9) |
|
28008149 | |
| Growth inhibition assay | Cell viability Cell viability |
|
28008149 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT03582098 | Completed | Chronic Lymphocytic Leukaemia | Gilead Sciences | September 12 2018 | -- |
| NCT03151057 | Terminated | B Cells-Tumors|B Cell Chronic Lymphocytic Leukemia|Follicular Lymphoma|Mantle Cell Lymphoma|Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Gilead Sciences | July 31 2018 | Phase 1 |
| NCT03568929 | Completed | Follicular Non-Hodgkin''s Lymphoma Refractory | Gilead Sciences | May 25 2018 | -- |
化学信息&溶解度
| 分子量 | 415.42 | 分子式 | C22H18FN7O |
| CAS号 | 870281-82-6 | SDF | Download Idelalisib (CAL-101) SDF |
| Smiles | CCC(C1=NC2=C(C(=CC=C2)F)C(=O)N1C3=CC=CC=C3)NC4=NC=NC5=C4NC=N5 | ||
| 储存条件(自收到货起) | |||
|
体外溶解度 |
DMSO : 83 mg/mL ( 199.79 mM； DMSO吸湿会降低化合物溶解度，请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
摩尔浓度计算器 |
|
体内溶解度 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | ||||
|
点击购买：
|
|||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
常见问题及建议解决方法
问题 1:
What is the recommended dose of CAL-101 and the route of administration for mouse studies?
回答：
According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684
PI3K相关信号通路图
Tags: buy Idelalisib (CAL-101) | Idelalisib (CAL-101) supplier | purchase Idelalisib (CAL-101) | Idelalisib (CAL-101) cost | Idelalisib (CAL-101) manufacturer | order Idelalisib (CAL-101) | Idelalisib (CAL-101) distributor
Copyright 2013 Selleck中国. All Rights Reserved.
沪ICP备13045345号-1沪公网安备 31011502012800号